NurExone Demonstrates Scalable Exosome Production

NurExone Biologic Inc. has successfully doubled its exosome production by operating two bioreactors in parallel, maintaining production time and process consistency. The company is implementing a 'scaling out' strategy to add standardized production units, which aims to protect capital while meeting commercial demand. This initiative is being developed through its U.S. subsidiary, Exo-Top Inc., in collaboration with Made Scientific. NurExone is also advancing its dual-track strategy focusing on regulated exosome therapies and commercial opportunities.